Lilly boosts guidance on strong demand for obesity drugs

Mounjaro, the company’s diabetes medicine, surpassed all estimates in the period as access to the drug has increased around the world.

The Eli Lilly manufacturing plant in Kinsale. Photographer: Paulo Nunes dos Santos/Bloomberg

Eli Lilly raised its 2026 sales guidance after it reported far stronger second-quarter demand than analysts expected for its weight-loss and diabetes drugs.

Sales for the year will be $85bn (€73.6bn) to $87bn (€75.3bn), Lilly said on Wednesday, compared with its earlier forecast of $82bn to $85bn. Its second-quarter adjusted earnings and revenue beat Wall Street estimates.